Schizophrenia is a life long affliction. There is no permanent cure for this illness. However, numerous drugs have made the effective management of the disease a reality.
This briefing examines both corrent and emerging therapeutic approaches for the management of schizophrenia. It provides an analysis of the current and future markets for these agents, including forecasts to 2009 segmented by geographic region and by type of drug and likely market scenarios for new agents not yet available. The briefing discusses the drugs currently in clinical trials, provides epidemiological information, and profiles the major competitors.
The information presented in this report is the result of primary and secondary research. Secondary research included data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. Primary research consisted of interviews and correspondance with company executives, clinicians, researchers and public health officials. The market forecasts are based on epidemiology, historical growth rates, probable product introductions, analyst expectations, and expert consensus.